And

are now a part of the new and improved

search Created with Sketch.
search Created with Sketch.

Advertisement

Dermwire News

News | June 4, 2020

Potential Stem Cell Research Breakthrough: Researchers Grow Hairy Skin from Human Stem Cells

Scientists from Indiana University School of Medicine and Harvard Medical School have determined how to grow hairy skin using human stem cells. Their study, published in Nature, shows that skin generated from...

Read More

News | June 4, 2020

Pfizer’s JAK Inhibitor Improves Mild-to-Moderate AD Symptoms

Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief that this Janus kinase 1 (JAK1) inhibitor offers patients living with moderate to severe atopic dermatitis (AD). Abrocitinib is an...

Read More

News | June 4, 2020

Tremfya Shows Improvement in PsA Joint and Skin Symptoms

Tremfya (guselkumab) demonstrated improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52 in adult patients...

Read More

News | June 3, 2020

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and AD

Kymera Therapeutics Inc. has started  enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally...

Read More

News | June 2, 2020

Asana BioSciences’ JAK/SYK Inhibitor Performs Well in Phase 2b Study of Hand Eczema

Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adult patients with...

Read More

Advertisement

The Latest News

Advertisement

View more